ATIM-28. PHASE 2 STUDY OF ERC1671 PLUS BEVACIZUMAB VS BEVACIZUMAB PLUS PLACEBO IN RECURRENT GBM INTERIM RESULTS AND CORRELATIONS WITH CD4+ T LYMPHOCYTE COUNTS

類似資料

• Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4(+) T-lymphocyte counts
  著者:: Bota, Daniela A, 等
  出版事項: (2018)
• HOUT-17. A PRELIMINARY DATA REPORT ON A PHASE 2 STUDY OF ERC1671 IN RECURRENT GLIOBLASTOMA
  著者:: Bota, Daniela, 等
  出版事項: (2017)
• ATIM-42. DOUBLE-BLINDED, PLACEBO CONTROLLED PHASE 2 STUDY OF ERC1671 IN RECURRENT GLIOBLASTOMA: OS CORRELATIONS WITH INITIAL AND MAXIMUM CD4+T LYMPHOCYTE COUNT IN THE PERIPHERAL BLOOD
  著者:: Bota, Daniela, 等
  出版事項: (2019)
• CTIM-09. DOUBLE-BLINDED, PLACEBO CONTROLLED PHASE 2 STUDY OF ERC1671 IN RECURRENT GLIOBLASTOMA: VACCINE OVERALL SURVIVAL IN BEVACIZUMAB NAIVE AND BEVACIZUMAB RESISTANT PATIENTS
  著者:: Bota, Daniela, 等
  出版事項: (2020)
• Use of ERC-1671 Vaccine in a Patient with Recurrent Glioblastoma Multiforme after Progression during Bevacizumab Therapy: First Published Report
  著者:: Bota, Daniela A, 等
  出版事項: (2015)